Bullpen.News · the best place to find stock ideas

GLOO: Gloo's own filings make the short case

Gloo's $3.25 follow-on, going-concern warning and $28.0 million first-half cash burn frame the short case against its acquisition-driven growth.

GLOO $298M

Guardian Research 28h ago 8 clicks

29h ago BMBL $783M

TSOH Weekly Roundup (10/16/2026)

TSOH Investment Research 6 clicks

Oct 15 DFH $764M

Problems at Dream Finders Homes (DFH)

Hunterbrook 12 clicks

From X

@majgeoinvesting Aug 20

Maj Soueidan on X

Can finally believe that $BOSC will make an acquisition? https://t.co/iMwgVmJvux

@blondesnmoney Aug 20

Cluseau Investments on X

$IESC is buying DBM Global from $VATE for $650 Million. Not sure if I am missing something, but DBM's backlog is up 50% year over year, revenue up 25%, and they agreed to sell it for 11x earnings. What?

@KEDM_COM Aug 20

KEDM.com on X

McIntyre Partnerships @Mc_Partnerships considers QuidelOrtho $QDEL a once-in-a-decade opportunity, as the company is reportedly selling its Point-of-Care division to deleverage and fund a share buyback. Note this was written before a potentially thesis-changing Q2. Previously flagged in KEDM Vol. 281.

@BlueDuckCap Aug 20 2 clicks

BDC on X

$XGN bio pharma revenue increased 40% yy in Q2 hitting a quarterly record. What we also love is that the stock trades for 2.5x sales vs a comp set at 10.3x. This is in advance of launching testing for Myositis which is another connective-tissue disorder that requires early diagnosis to treat and prevent serious organ damage. Rheumatologists have requested a calibrated Myositis test w/ 15x more frequency than any other test because the condition is so critical to rule out. Only $XGN will offer this and its coming in the 1H of 2027, maybe Q1 and the additional cost of launch are already baked into the cake.

@stockgutter Aug 20 1 click

SG on X

Worst analyst piece I have seen in years: Litchfield Hills Research puts a 12-month price target of $66 on $FFAI You will be shocked to learn that the small type says: "Litchfield Hills Research LLC has received compensation from the company for distribution and investor targeting services."

@stockgutter Aug 20 1 click

SG on X

$KSCP quarterly results improve but still stink. Now trades for about 1x annualized sales. Note that any valuation metric needs to be taken with a grain of salt here given the heavy dilution. https://t.co/oGq9fRNtNe

@cfrischer1 Aug 19

Charles Frischer on X

$KWY I have attached my notes on Kingsway. I think the company is at an inflection point based upon the excellent quarter they just announced. Very excited to see how the next few years play out for shareholders. I am optimistic. $10 per share should be an excellent entry point. https://t.co/j0rgEf3hUR

@DeepSailCapital Aug 19

Deep Sail Capital on X

@stockgutter @paulcerro I see 18% borrow rate on $MRNX . Was up 353% today. Wow.

Free Recaps of the best new stock ideas, delivered every morning.

Read past recaps

Park Aerospace: The Q2'27 Sell-Off Misreads a Sole-Source Defense Supplier

Park Aerospace’s 11% Q2’27 sell-off overlooks sole-source PAC-3 rocket-motor materials and A320neo engine composites, with missile capacity…

PKE $571M

Monte Independent Investment Research Oct 15 12 clicks

flyExclusive: Sell Despite Strong Turnaround

FlyExclusive posted 22% Q2 revenue growth and a 20.4% gross margin, but negative free cash flow, net debt and preferred capital leave…

FLYX $65M

Dhierin Bechai Oct 15 1 click

Private Equity Prints Multibaggers With This Pattern. No One is Talking About It.

Shenandoah Telecommunications’ Glo Fiber buildout ends this year, and private infrastructure investors’ repeated fiber deals frame a…

SHEN $556M

Phynvesting Oct 14 18 clicks

SED Energy: The 40% Dividend. Signal or Noise?

SED Energy's proposed Ventura merger projects a 22% to 40% dividend yield, but idle tender barges, debt and repayments materially reduce…

SBDXF $498M

Cannibal Stocks Oct 13 7 clicks

Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns

Cabaletta Bio's 40% sell-off leaves CABA below its $2.41 pipeline value ahead of pivotal rese-cel autoimmune data in 2027, despite dilution…

CABA $263M

Cypriot Invests Oct 13 2 clicks

Monte Investments Market Brief Vol. CXXXI

Park Aerospace reported 27% revenue growth and 72% EPS growth, supported by composite materials for Airbus engines and PAC-3 rocket motors.

PKE $571M

Monte Independent Investment Research Oct 13 4 clicks

H&R REIT, an opportunity in a corrupt process

H&R REIT's proposed GO Residential transaction faces investor opposition over rejected $12.50 cash bids, insider benefits and tax…

GONYF $499M

Nugget Capital Partner's Substack Oct 12 2 clicks

Hippo Holdings ($HIPO): The Insurtech That Stopped Chasing Hype and Started Making Money

Hippo’s insurance platform posted 61% premium growth, a 95.8% combined ratio and a fifth profitable quarter as it shifted toward carrier…

HIPO $931M

Substack von Philipp Oct 10 8 clicks

Brazil Potash: Bull Case Is Starting To (Slowly) Bloom

Brazil Potash has secured court support and a power agreement, but financing, dilution and potash-price-sensitive EBITDA remain central…

GRO $130M

Wolf Report Oct 10 3 clicks

Hyster Yale (HY) Multibagger potential as confluence of negatives subside. Attractive after markets part services model

Hyster-Yale trades at 0.16 times sales as lift-truck bookings rebound and restructuring targets $85 million to $100 million in annual…

HY $524M

Calvin Blissett Oct 9 3 clicks

FULC · long

Fulcrum Therapeutics INC

Fulcrum Therapeutics trades below cash as it pursues a likely reverse merger, creating a biotech shell opportunity.

FULC $280M

Value Investors Club Jul 19

El Pollo Loco: New York State Of Mind

El Pollo Loco plans 18 to 20 FY26 openings, including 15 franchised New York stores over five years, as asset-light expansion and…

LOCO $499M

Pedro Goulart Oct 14 1 click

Namib Minerals: Research Note

Namib Minerals posted H1 adjusted EBITDA of $19.0 million, up 76%, as higher gold prices offset lower production.

NAMM $55M

Atrium Research - Equity Research Oct 8 3 clicks

Lesaka: A $4.69 Stock With a $20–30 Case

Lesaka CEO Ali Mazanderani has bought more than $10 million of stock while pursuing a $20 to $30 valuation case through targeted…

LSAK $384M

Mispriced Assets Oct 8 5 clicks

What I’ve Been Up To

Cogent Communications and AI data-center bottlenecks feature in a newsletter update on recruiting, financial media and conference takeaways.

CCOI $428M

Stock Thoughts Oct 7 4 clicks

Lesaka: Why He's Betting Big | Ali Mazanderani | Ep. 5

Lesaka’s executive chairman has invested more than $10 million personally and targets EPS compounding above 40% through consumer, merchant…

LSAK $384M

Mispriced Assets Oct 7 2 clicks

VersaBank: Expensive, But Growth Still Justifies A Buy

VersaBank's Q3 revenue rose 23% and adjusted net income 27%, while a 2.19% net interest margin and 19.15x forward earnings temper its 2027…

VBNK $707M

Grassroots Trading Oct 6 2 clicks

MGP Ingredients (MGPI) - The Hangover After the Whiskey Boom

MGP Ingredients trades at 0.74 times tangible book after whiskey oversupply drove sales declines and more than $400 million of impairments.

MGPI $308M

Dismissed & Asset-Backed Oct 6 1 click

DMRC: 31 retailers in line, up from one

Digimarc’s gift-card watermark pilot found zero fraud at Schnucks, while its retailer pipeline rose to 31 from one in 2025 despite…

DMRC $181M

Trade Ideas Flow Oct 5

Nyxoah: Label Expansion Set To Unlock A Monopoly In A Billion Dollar Market.

Nyxoah's Genio implant could reach CCC patients after an FDA label expansion, targeting 30% of the obstructive sleep apnea device market by…

NYXH $112M

Stephen Tobin Oct 5 3 clicks

Latest News

Maj Soueidan on X

Cluseau Investments on X

KEDM.com on X

BDC on X

SG on X

SG on X

Charles Frischer on X

Deep Sail Capital on X

Investor Letters

Recent recaps

Latest recap

Publications we follow

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 52 of 235

X accounts we follow

Investor letters we follow

Sectors